Tag Archives: Taxotere

A New Method to Treat Chemotherapy-Induced Neuropathic Pain

Posted on March 12, 2012 by wngai

If you are cancer patients and have to receive chemotherapy agents such as taxanes (paclitaxol- Taxol and docetaxel-Taxotere), vinca alkaloids (vinorelbine-Navelbine) and platinum compounds (cisplatin, carboplatin – Paraplatin and oxaliplatin – Eloxatin), it is likely that you might experience chemotherapy … Continue reading →

Posted in Anal Cancer, Bladder Cancer, Breast cancer, Cancer, Colorectal cancer, Endometrial Cancer, Esophageal Cancer, Gallbladder cancer, Gastric Cancer, Glioblastma, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate cancer, Renal Cancer, Small Cell Lung Cancer | Tagged , , , , , , , , , , , , , , , , | Comments Off on A New Method to Treat Chemotherapy-Induced Neuropathic Pain

New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

Posted on March 5, 2012 by wngai

Excellent news for prostate cancer patients whose cancer has progressed after hormonal treatment and chemotherapy!   An experimental oral agent, MDV3100 (Medivation) was found to improve survival in metastatic castration-resistant prostate cancer by 4.8 months The new agent, called MDV3100, is … Continue reading →

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , , , , , , , , , , | Comments Off on New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

A New Agent That Might Change the Lives of Many Cancer Patients

Posted on October 16, 2011 by wngai

This is not only good news for all prostate cancer patients, but is also good news for all cancer patients. The investigational radiopharmaceutical radium-223 chloride (Alpharadin) has recently been shown to improve survival in patients with advanced prostate cancer and … Continue reading →

Posted in Anal Cancer, Bladder Cancer, Breast cancer, Cancer, Colorectal cancer, Endometrial Cancer, Esophageal Cancer, Gallbladder cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate cancer, Renal Cancer, Small Cell Lung Cancer, Thyroid Cancer | Tagged , , , , , , , , , , , , , , , , , | Comments Off on A New Agent That Might Change the Lives of Many Cancer Patients

Docetaxel (Taxotere) is Effective in Heavily Pretreated Nasopharyngeal Carcinoma Patients

Posted on March 6, 2011 by wngai

It is well-established that nasopharyngeal carcinoma (NPC) is a chemo-responsive disease.  Despite improved outcome with chemo-radiation (platimum-based chemotherapy with radiation), treatment failure continue to be a problem in patients with locally advanced Stage III/IV disease.  Now, a new study published … Continue reading →

Posted in Cancer, Nasopharyngeal Cancer | Tagged , , , , , , , | Comments Off on Docetaxel (Taxotere) is Effective in Heavily Pretreated Nasopharyngeal Carcinoma Patients

Another Option in the Second Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

Posted on April 25, 2010 by wngai

Docetaxel(Taxotere) has long been considered the standard of care for second-line treatment of advanced NSCLC.  However, the disadvantage of using this agent include the need to administer it with corticosteroid premedication and its toxicity profile A new study published in … Continue reading →

Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , | Comments Off on Another Option in the Second Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)